OptimizeRx (NASDAQ:OPRX) Given New $10.00 Price Target at Lake Street Capital

Key Points

• Lake Street Capital cut its OptimizeRx price target to $10 from $11 but kept a Buy rating, implying 33.78% upside from the share price cited in the report.
• Analyst sentiment remains broadly positive: MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $11.21, despite several firms lowering their targets.
• OptimizeRx beat quarterly estimates, reporting EPS of $0.20 versus $0.16 expected and revenue of $21.61 million versus $21.19 million expected.

OptimizeRx (NASDAQ:OPRX - Get Free Report) had its price objective reduced by Lake Street Capital from $11.00 to $10.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a "buy" rating on the stock. Lake Street Capital's price target suggests a potential upside of 33.78% from the company's current price.

Other equities analysts also recently issued research reports about the company. Wall Street Zen downgraded OptimizeRx from a "strong-buy" rating to a "buy" rating in a research report on Monday, July 20th. Weiss Ratings upgraded shares of OptimizeRx from a "sell (d)" rating to a "sell (d+)" rating in a report on Tuesday, August 25th. Stifel Nicolaus reduced their price target on shares of OptimizeRx from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Thursday. Citigroup reiterated a "market outperform" rating on shares of OptimizeRx in a report on Tuesday, October 27th. Finally, B. Riley Financial restated a "buy" rating and issued a $10.50 target price (down from $11.00) on shares of OptimizeRx in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, OptimizeRx presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.21.

OptimizeRx Price Performance

Shares of NASDAQ OPRX traded down $1.48 during midday trading on Thursday, reaching $7.47. 892,944 shares of the stock traded hands, compared to its average volume of 353,337. The stock has a market capitalization of $140.83 million, a PE ratio of 32.70 and a beta of 1.20. The company's 50 day moving average is $8.43 and its 200 day moving average is $7.24. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.58 and a quick ratio of 5.58. OptimizeRx has a one year low of $4.54 and a one year high of $16.37.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.16 by $0.04. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The business had revenue of $21.61 million during the quarter, compared to analyst estimates of $21.19 million. On average, equities research analysts anticipate that OptimizeRx will post 0.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC purchased a new position in shares of OptimizeRx in the 1st quarter valued at about $85,000. Corient Private Wealth LP purchased a new position in OptimizeRx during the second quarter worth about $77,000. Cetera Investment Advisers acquired a new position in OptimizeRx in the 1st quarter valued at about $173,000. State of Wyoming boosted its holdings in OptimizeRx by 234.6% in the 1st quarter. State of Wyoming now owns 35,251 shares of the company's stock valued at $221,000 after purchasing an additional 24,716 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its holdings in OptimizeRx by 180.1% in the 1st quarter. Quantinno Capital Management LP now owns 49,022 shares of the company's stock valued at $308,000 after purchasing an additional 31,518 shares during the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

More OptimizeRx News

Investors following OPRX have been watching these news items:

• Positive Sentiment: Q3 adjusted earnings were $0.20 per share, topping estimates of $0.16–$0.18, while revenue of about $21.6 million exceeded the roughly $21.2 million consensus. OptimizeRx Q3 2026 results and guidance
• Neutral Sentiment: B. Riley and Stifel Nicolaus maintained Buy ratings, though they lowered their price targets to $10.50 and $11, respectively—signaling continued optimism but more cautious valuation expectations. B. Riley ratings Stifel Nicolaus ratings
• Negative Sentiment: OptimizeRx forecast FY 2026 revenue of $87 million–$93 million, below the $96.2 million analyst consensus. The weaker outlook may overshadow the quarterly earnings and revenue beats. Company results and guidance

About OptimizeRx

OptimizeRx Corporation NASDAQ: OPRX is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.